Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Q1 2018 Earnings Presentation
16 slides from Niagen Bioscience's earnings presentation, May 10, 2018
Slide 1: Earnings Conference Call First Quarter 2018
Earnings Conference Call First Quarter 2018 _Frank Jaksch — Co- ~ ~ Founder/CEO ss = Rob Fried — President/coo Kevin Farr - cro
Slide 2: etait et tna reenter ele eter wet om
etait et tna reenter ele eter wet om ciara see es
Slide 3: Science Continues to Expand
Science Continues to Expand + 18 human studies in various stages, up from 14 at end of 4%” Quarter 2017 + Mitochondrial biogenesis ~ University of Cambridge + Systolic heart health — University of Washington + Amnestic mild cognitive impairment — University of Delaware + Metabolism and vascular func
Slide 4: >$50 million of research funded by other parties
>$50 million of NR research funded by other parties + Ahem’ ease + Wee ors + Breast Cancer Neuropathy NIvERSHryo" BIRMINGHAM HH sr pone Meoiear OUCIwine viene UNIVERSITY of WASHINGTON nselous UCPAVIS rrAL W@ Dartmouth
Slide 5: Growth of TRU NIAGEN exceeds plan
—_—— Growth of QD TRUNIAGEN exceeds plan * TRU NIAGEN sales show strong growth + 71% of total NIAGEN-related sales vs. 1% last year + E-commerce sales of TRU NIAGEN in the U.S. compounding at over 25% month/month * NIAGEN-Related sales quadrupled Year-over-Year Q1’18 vs. Qt’17 * 65% of total sales v
Slide 6: Building a Global Brand
buicing a Global Brand
Slide 7: Management Team
Management Team Frank aksch - CEO (soon to be Executive Chairman) (Cosounded ChromaDex in 2000 Rob Fried - President and COO (s00n to be CEO) Board member since 2015, President, CEO and Director of Ideation Acquistion Corp. 2008-2011, Founder and CEO of Feeln 2007-2017 (acquired by Hallmark Cards ne
Slide 8: Our Scientific Advisory Board
Our Scientific Advisory Board Charles Brenner, Ph.0. Head of Biochemistry University of lowa World's Foremost Authority on NAD Metabolism Roger Kornberg, Ph.0. Professor of Structural Biology Stanford University ‘Nobel Prize Winner, Chemistry, 2006 Dr. Bruce German Chairman of Food, Nutrition, & Hea
Slide 9: Financial Highlights
Slide 10: Q1 2018 Net Sales Up 95% to $6.6 Million, Fueled by Growth of TRU NIAGEN
Qi 2018 Net Sales Up 95% to $6.6 Million, Fueled by Growth of TRU NIAGEN® + TRU NIAGEN sales were 71% of total NIAGEN-related sales in Q1 2018 + NIAGEN-related sales in Q1 2018 grew 337% compared to Ql 2017 + NIAGEN-related sales in Q1 2018 were 65% of total sales, compared to 29% in Q1 2017 12018 N
Slide 11: NIAGEN Related Sales – Q1 2017 vs. Q1 2018, +337%
—_—— NIAGEN Related Sales ~ Qi 2017 vs. Q1 2018, +337%
Slide 12: Q1 2018 Profit and Loss
<= Q1 2018 Profit and Loss toca et 5) Levan _ere7 water B58 98 o8 92 & 43 i aE af 3
Slide 13: Q1 2017 Operating Loss vs. Q1 2018
—_—— Q1 2017 Operating Loss vs. Q1 2018 (inmaons) ys say sen wy + uo) cos : iw o iw aurai Volume Ecommerce Legal «Shae RAD ansar Operating ‘Same Beod creme «SGA Operating ss Marketing come ‘oes
Slide 14: Q1 2018 Net Cash Used in Operating Activities
Q1 2018 Net Cash Used in Operating Activities “we Mette uote (cases) mor 701 Choe hota Cat mo hen charge AP. re $a sas “Surtees ompatin oe “Se ms ms _vova ‘areca st Kron cee) ae ee Steger cng ees aor 1s ey mt) Recetas: oa —— 2) oe capa cents (10) Oar acre iatates ea (sn sso ste ss Irecaonrow «som nh
Slide 15: 2018 Outlook
2018 Outlook * Significant growth in revenues * Gross profit % of net sales continues to expand * Investment spending ahead of revenue growth Marketing Global infrastructure Team R&D + Protecting/managing patent portfolio and trademarks * TRU NIAGEN is expected to make a positive contribution to par
Slide 16: Contact Info
—— Contact Info Andrew Johnson Director of investor Relations T: #1.310.388,6706 Ext. 661 Andrew\@chromadexcom ‘wwn.chromadex.com